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Abstracts / Urological Science 26 (2015) S50eS81S72carried at least one C allele at rs187238 had a 2.760efold risk of UCC.
However, the rs1946518 and rs187238 polymorphisms of the IL-18 gene
did not affect tumor stage among the UCC patients.
Conclusion: The rs187238 polymorphic genotypes of IL-18 might
contribute to the susceptibility of UCC and the synergic effect of smoking
was also demonstrated.
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Introduction: There are many possible causes of hematuria including:
urinary tract infection, urolithiasis, tumor in kidney or bladder, exercise,
drug, bleeding disorder or trauma. Herein we report a case of hematuria
with bladder tamponade due to gallbladder cancer metastasis
Case report: A 61-year-old women presented with gross hematuria,
nausea, vomiting to our ER for help. According to the statement of her, DM,
CRI, gallbladder stone, cancer post operation. Sonography revealed bladder
tamponade and left hydronephrosis. Due to poor condition, CT scan was
performed and revealed much bladder clot, left hydronephrosis, ascites
and favored carcinomatosis. Emergent cystoscopy removed blood and
bladder tumor was noted. TURBT was performed and pathology revealed
gallbladder cancer metastasis
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Purpose: Visfatin, a newly discovered adipocytokine, is a pro-inﬂamma-
tory cytokine. This study aimed to evaluate the predictive value of visfatin
on prognosis of patients with upper tract urothelial carcinoma.
Materials andMethods: One-hundred and ﬁve patients (median age¼ 64,
range ¼ 24-84 years) were included in this study. Visfatin expression in
upper tract urothelial carcinoma tissues was analyzed by immunohisto-
chemistry. Visfatin expression was correlated with clinicopathologic var-
iables using the c2 test. The prognostic value of visfatin for recurrence-free
and cance-speciﬁc survival was evaluated by Kaplan-Meier estimates, and
the signiﬁcance of differences between curves was evaluated by the log-
rank test. Cox regression model was also used to evaluate the hazard ratios
of visfatin on survival.
Results: High visfatin expression in upper tract urothelial carcinoma tis-
sues was signiﬁcantly correlated with tumor stage (p ¼ 0.001), grade
(p ¼ 0.007) and p53 expression (p ¼ 0.07). High visfatin expression was
associated with poor recurrence-free and cancer-speciﬁc survival. Cox
regression analysis also revealed that visfatin is an independent predictor
of recurrence-free (HR ¼ 3.22, p ¼ 0.009) and cancer-speciﬁc survival
(HR ¼ 5.74, p ¼ 0.023).
Conclusion: Our ﬁndings indicated that higher visfatin expression is a
potential biomarker to predict patient survival. Further study is necessary
to investigate the molecular mechanisms of visfatin involved in the
cancerous processes of upper tract urothelial carcinoma.NDP088:
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Purpose: Signal transducers and activators of transcription (STATs) play an
important role in gene regulation, cell proliferation and differentiation.We
aimed to establish the relationship between STAT3 expression and the
prognosis of upper tract urothelial carcinoma (UTUC).
Materials and Methods: This study retrospectively reviewed 100 patients
with pathologically conﬁrmed UTUC at Kaohsiung Medical University
Hospital. We quantify the expressions of STAT3 in cancer cells by immu-
nohistochemistry method, and determine the clinicopathologic signiﬁ-
cance between expression of STAT3 and prognostic outcome in patients
with UTUC.
Results: High STAT3 expression was detected in 52% of whole UTUC pa-
tients. High STAT3 expression was associated with poor recurrence-free
(p ¼ 0.018) and overall survival (p ¼ 0.026). In the advanced cancer
(stageT3/T4), STAT3 expression is the only independent prognostic factor
for recurrence-free survival (hazard ratio ¼ 5.91, p ¼ 0.01) and cancer-
speciﬁc survival (hazard ratio ¼ 8.83, p ¼ 0.039).
Conclusion: In UTUC, the STAT3 can be a potential prognostic marker for
cancer recurrence and survival, especially in the advanced stage.
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Purpose:We present our experience with the clinical feature, efﬁcacy and
outcome of comparison of partial nephrectomy and radiofrequency abla-
tion (RFA) for small renal tumors in the manner of Preoperative Aspects
and Dimensions Used for an Anatomical (PADUA) Classiﬁcation as a min-
imal invasive treatment in VGHKS
Materials and Methods: A total of 78 patients in 15 years with small renal
tumors were enrolled. We use Preoperative Aspects and Dimensions Used
for an Anatomical (PADUA) Classiﬁcation for renal tumor classiﬁcation and
compared PN (42 patients) and RFA (36 patients) with clinical outcome
(local recurrence-free, metastases-free, and overall survival rates), RFA
procedure (RFA needle, No. of treatment, Anesthesia, complication), renal
function deterioration after procedure and pathology report. We also use
clustered needle or switch mode control of RFA and D5W instillation for
separating bowel loop.
Results: The median value of the PADUA score was 7.5 (IQR: 7e9), which is
no signiﬁcant difference between two groups. Of the 56 cT1a patients, 32
underwent PN, 24 underwent RFA. In this cohort, local recurrence-free
survival, metastases-free survival were similar among the two treatments
(p¼ 0.53 / 0.46). Of the 22 cT1b patients, 10 patients underwent PN, and 12
patients were managed with RFA. In this cohort, local recurrence-free
survival (p ¼ 0.76) and metastases-free survival (p ¼ 0.51) were similar
between PN and RFA. In both the cT1a and cT1b groups, PN patients were
signiﬁcantly younger, with lower Charlson scores and had superior overall
survival (p < 0.001 for all). In the RFA group, all patients have been biopsy
